0001179110-18-004708.txt : 20180320
0001179110-18-004708.hdr.sgml : 20180320
20180320200229
ACCESSION NUMBER: 0001179110-18-004708
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180316
FILED AS OF DATE: 20180320
DATE AS OF CHANGE: 20180320
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Haviland Kate
CENTRAL INDEX KEY: 0001663022
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37359
FILM NUMBER: 18703150
MAIL ADDRESS:
STREET 1: BLUEPRINT MEDICINES CORPORATION
STREET 2: 38 SIDNEY STREET, SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Blueprint Medicines Corp
CENTRAL INDEX KEY: 0001597264
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 45 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-374-7580
MAIL ADDRESS:
STREET 1: 45 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2018-03-16
0
0001597264
Blueprint Medicines Corp
BPMC
0001663022
Haviland Kate
C/O BLUEPRINT MEDICINES CORPORATION
45 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
Chief Business Officer
Common Stock
2018-03-16
4
M
0
1571
16.28
A
7445
D
Common Stock
2018-03-16
4
M
0
2500
36.05
A
9945
D
Common Stock
2018-03-16
4
S
0
500
102.19
D
9445
D
Common Stock
2018-03-16
4
S
0
1800
101.32
D
7645
D
Common Stock
2018-03-16
4
S
0
1200
100.02
D
6445
D
Common Stock
2018-03-16
4
S
0
571
99.20
D
5874
D
Stock Option (Right to Buy)
16.28
2018-03-16
4
M
0
1571
0
D
2026-02-01
Common Stock
1571
120639
D
Stock Option (Right to Buy)
36.05
2018-03-16
4
M
0
2500
0
D
2027-02-16
Common Stock
2500
118139
D
The exercises reported on this Form 4 was effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Exchange Act.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.90 to $102.84 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (6) to this Form 4.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.98 to $101.80 per share.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.66 to $100.54 per share.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.73 to $99.50 per share.
This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.
This option was granted on February 16, 2017. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.
/s/ Christopher Frankenfield, Attorney-in-Fact
2018-03-20